Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 4

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 29Other hematologic neoplasm 10Thoracic 8Gastrointestinal 7CNS 7Plasma cell 6Head & Neck 5Tumor-Agnostic 4Lymphoid 4Endocrine 4Myeloid 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Multiple Myeloma 4Lymphoma 4Hematologic Neoplasms 4

Interventions

Rituximab 530Cyclophosphamide 425Vincristine 219Doxorubicin 192fludarabine phosphate 177Etoposide 167Prednisone 166fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Antilymphocyte Serum 55Brentuximab Vedotin 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × trametinib × Lymphoid × Clear all
NCT04439292 2026-06-02

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439279 2026-05-07

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
4 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡